An interventional study of Nonalcoholic red wine group (Intervention group) and Drinking water group (Control group) in Cognitive Disorders and Muscular Disorders, Atrophic, sponsored by University Rovira i Virgili. Recruiting at 3 sites in Spain. Open to participants aged 60 Years to 74 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-05.
Sponsored by University Rovira i Virgili · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 162 studies in Cognitive Dysfunction with a site in Spain — 44 open to participants now, 61 under way, 9 of them phase 3. Cognitive Dysfunction · Spain.
Among the 162 studies in Cognitive Dysfunction with a site in Spain, this one is the 88th largest by planned enrollment of the 127 interventional ones that give a count, is one of 16 that started in 2025, is one of 91 with no phase, reaches primary completion later than 23 of the 60 other live ones, and was the 128th registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →44 of the 162 studies in Cognitive Dysfunction with a site in Spain are open now. Recruiting first, the newest first:
Consorci Sanitari de l'Alt Penedès i Garraf · Sites in Spain
Ages 70+
Biogipuzkoa Health Research Institute · Sites in Spain
Ages 18+
Consorci Sanitari de Terrassa · Sites in Spain
Ages 65+ · Healthy volunteers
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation · Sites in Spain, Australia, Austria and 14 more countries
Ages 18+
Universidad Complutense de Madrid · Sites in Spain
Ages 65–85
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 60 Years to 74 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
162 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 19 · Phase 3 16 · Phase 4 3
First in 2004; this study’s year is marked. 16 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 72 is above the median of 64 across 2,804 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 100 across the 127 interventional studies, 250 across the 35 observational. Of the 77 that completed or were terminated, 17 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 162 have an industry lead sponsor. The 10 most frequent:
University Rovira i Virgili is the lead sponsor of 53 studies on the registry; 10 are open to participants now.
University Rovira i Virgili has 3 studies filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
14 of the studies in Cognitive Dysfunction with a site in Spain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT07802392Consorci Sanitari de TerrassaImmersive Nature-Based Wellbeing Program in Older Adults With Cognitive Impairment | 2026-11 |
| NCT07793682Althaia Xarxa Assistencial Universitària de ManresaEarly Neuropsychological Rehabilitation and Family Psychoeducation After Ischemic Stroke | 2026-11-25 |
| NCT06956794Consorci Sanitari de TerrassaMultimodal Training With Immersive Virtual Reality to Improve the Cognitive Health and Emotional Well-being of Older Women Living Alone | 2026-12-01 |
| NCT05289258Universidad de CórdobaUnified Barlow Protocol (UP) in Cancer Survivors for Cognitive Impairments | 2026-12-30 |
Add all 14 to your calendar (.ics) → With an account.
Among the 162 studies in Cognitive Dysfunction with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Polyphenols, precisely resveratrol, with red wine as the most substantial source, was associated with improvements in cognitive function. Also, the loss of muscle mass and strength in elderly, that significantly increases dependency of these people, it could be attributed to alterations in gut microbiota through the "gut-muscle axis" and this underline the urgent need to efficiently find out any intervention or preventive approach via modulation of gut microbiota to improve muscle function in elderly. In this context, red wine polyphenols exert their effects through interaction with gut microbiota following the well-known two-way interaction between polyphenols and gut microbiota by promoting the proliferation of beneficial bacteria and increasing their abundance. Similarly, aging cognitive decline can be modulate by microbiota, notably through "gut-brain axis". Additionally, dietary polyphenols can delay inflammation or/and oxidation on the onset of age-related cognitive decline or muscular oxidation or cardiovascular factors risk factors, all of them relevant factors for the onset of physical frailty and dependence in elderly.
Moreover, wine is a singular alcoholic beverage with a high content of phenolic compounds of a very diverse nature on which numerous protective effects on health have been described. In fact, wine, in addition to alcohol, contains a complex mixture of polyphenols, including anthocyanins and non-coloured phenols as proanthocyanidins, flavonols, hydroxycinnamic and hydroxybenzoic acids, stilbenes and lignans. Thus, the bioprotective effects of wine polyphenols could be the consequence of the synergistic effect of this complex mixture of polyphenols from the grape and the winemaking process. That is why it is essential to clarify whether consumption of polyphenols from red wine provided by a nonalcohol red wine within a healthy diet can produce beneficial effects on health, differentiating this pattern from a general consumption of alcohol generally associated with negative effects. Based on the ethical limitations to carry out diet intervention studies with wine in humans, this project proposes the use of a nonalcoholic wine as vehicle of the complex mixture of red wine polyphenols.
The hypothesis of our research is that regular consumption of red wine polyphenols, 150 mg/day, delivered through a nonalcoholic red wine, in the context of a Mediterranean diet (MD pattern), could promote protective mechanisms for a healthy aging, especially through its beneficial effects on cognitive and locomotor abilities and mediated by the modulation of the intestinal microbiota (composition, function and associated metabolome). The main objective of the WinAging project is to add knowledge concerning the diet modulation of molecular mechanisms of the aging process through multi-omic approaches based on the potential health effects of a dietary strategy by a sustained MD supplementation with nonalcoholic red wine rich in polyphenols to tackle cognitive and locomotor abilities in early elderly home-dwelling subjects.
The specific objectives:
Objective 2. To evaluate the chronic effects of the intake of wine polyphenols (average dose 150 mg/day) delivered through a nonalcoholic red wine in the context of a MD in early elderly home-dwelling subjects, and applying participatory research to increase adherence of subjects in the clinical intervention study.
Objective 3. To unravel the underlying mechanisms involved in the potential beneficial effects of red wine polyphenols on aging.
A total of 72 home-dwelling early elderly volunteers (men and women) 60-74 years old will be included in the intervention (36 in each arm of the intervention).
During the study there will be 11 visits in total. Visits will be every 4 weeks form the V1. The study visits will be the following:
Final study visit (V10). In visits V0, V1, V4, V7 and V10 volunteers must present themselves in fasting conditions of 8 hours to obtain fasting blood samples.
Basal visit (V1; week 0):
Administration of red nonalcoholic wine through opaque bottles to protect from light.
In a subsample of n= 15 subjects/group, 5 days before or after the visit V1, volunteers must have a:
Telephone visits: (V2 and V3; week 4 and 8):
Schedule the next visit and instructions.
3-month study visit (V4; week 12):
Telephone visits: (V5 and V6; week 16 and 20):
Schedule the next visit and instructions. 6-month study visit (V7; week 24):
Telephone visits: (V8 and V9; week 28, and 32):
Final visit (V10; week 36):
Collection of urine samples. *In a subsample of n= 15 subjects/group, 5 days before or after the visit V10.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1. Men or women between 60-74 years old; Sensory tolerance to red wine; Written provided before the initial screening visit.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Mediteranean diet + nonalcoholic red wine
Dietary Supplement: Nonalcoholic red wine group (Intervention group)
Mediterranean diet + drinking water
Dietary Supplement: Drinking water group (Control group)
Mediteranean diet + nonalcoholic red wine (300 mL wine/day, equivalent to a daily dose of 150 mg red wine polyphenols/day, during meals)
Mediterranean diet + drinking water (300 mL/day, during meals)
Cognitive function
The MMSE test for cognitive function. The total test score ranges from 0 (impaired) to 30 (normal) (Beaman et al., 2004).
Time frame: Visit 0 (week -1), visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)
Muscle strength
The muscle strength based on handgrip dynamometry (Jamar dynamometer; Sammons Preston Rolyan, Bolingbrook, IL)
Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)
Anthropometric measures
WC: waist circumference (cm) measured by steel measuring tape (at the umbilicus)
Time frame: Visit 0 (week -1), visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)
Anthropometric measures
Height (cm) measured by wall-mounted stadiometer (Tanita Leicester Portable; Tanita Corp., Barcelona, Spain)
Time frame: Visit 0 (week -1), visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)
Anthropometric measures
Weight (kg) measured by calibrated scale (TANITA MC-780MA; Tanita Corp., Tokyo, Japan).
Time frame: Visit 0 (week -1), visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)
Anthropometric measures
BMI (kg/m2) calculated by weight (kg) divided to height (m2).
Time frame: Visit 0 (week -1), visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)
Anthropometric measures
Body composition (Fat mass (% and kg)) measured by calibrated scale (TANITA MC-780MA; Tanita Corp., Tokyo, Japan).
Time frame: Visit 0 (week -1), visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)
Physical activity compliance
International physical activity questionnaire for elderly: IPAQ for elderly IPAQ-E Spanish version (Rubio-Castañeda et al., 2017). Higher scores mean a better outcome.
Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)
Sedentary habits
Questionnaire developed by Marshall et al 2010. Higher amount of hours mean bad outcome.
Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)
Sleep quality
Pittsburgh questionnaire (Buysse et al., 1989). The maximum score is 21 points. More than 5 points are considered bad outcomes and sleep problems, and less than 5 points are considered better outcomes and no sleep problems.
Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)
Life quality
SF-36 Health survey questionnaire (Ware \& Sherbourne, 1992). Higher scores mean a better outcome.
Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)
Depressive symptoms
Geriatric Depression Scale Questionnaire (Yesavage et al., 1983). The maximum puntuation is 15. The score is 0-4 no depression, 5-8 mild depression, 9-11 moderate depression and 12-15 severe depression.
Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)
Nutritional intake
3-day dietary record
Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)
Nutritional intake
FFQ MD adherence to assess food groups intake (Martinez-Gonzalez et al., 2012) Higher scores mean a better outcome.
Time frame: Visit 1 (week 0), visit 2 (week 4), visit 3 (week 8), visit 4 (week 12), visit 5 (week 16), visit 6 (week 20), visit 7 (week 24), visit 8 (week 28), visit 9 (week 32), visit 10 (week 36))
Nutritional status
Mini Nutrition Assessment (MNA)
Time frame: Visit 0 (week -1)
Nutritional status
Total cholesterol (mmol/L) by standardized methods in an automated analyzer (Beckman Coulter-Synchron (Galway, Ireland) in blood samples
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Nutritional status
Albumin (g/dl) by standardized methods in an automated analyzer (Beckman Coulter-Synchron (Galway, Ireland) in blood samples
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Nutritional status
Haemoglobin (g/dl) by standardized methods in an automated analyzer (Beckman Coulter-Synchron (Galway, Ireland) in blood samples
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Nutritional status
Vitamin D (ng/ml) by standardized methods in an automated analyzer (Beckman Coulter-Synchron (Galway, Ireland) in blood samples
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Nutritional status
Vitamin A (ug/dl) by standardized methods in an automated analyzer (Beckman Coulter-Synchron (Galway, Ireland) in blood samples
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Nutritional status
Vitamin E (mg/L) by standardized methods in an automated analyzer (Beckman Coulter-Synchron (Galway, Ireland) in blood samples
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Nutritional status
Carotenoids (ug/dl) by standardized methods in an automated analyzer (Beckman Coulter-Synchron (Galway, Ireland) in blood samples
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Cognitive function
Spanish validated Mini Mental State Examination test (MMSE). The MMSE test various cognitive. The total test score ranges from 0 (impaired) to 30 (normal) (Beaman et al., 2004).
Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)
Cognitive function
AD8. The AD8 (Alzheimer disease questionnaire) aids in identifying cognitive impairment. This test in combination with the Fototest, significantly increases the diagnosis accuracy of both tests (Carnero Pardo et al., 2012). The optimal cut-off point was 3/4.
Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)
Cognitive function
TAM test. TAM test (Memory alteration test) provides efficient and valid screening for amnestic Mild Cognitive Impairment and early stage Alzheimer's disease, and discriminates between them. The cut-off score is of 28 points (Rami et al., 2007).
Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)
Cognitive function
Fototest. The Fototest is useful to identify cognitive impairment and dementia in routine clinical practice. (Carnero Pardo et al., 2007). The cut off points are 25/26 for dementia and 28/29 for cognitive impairment.
Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)
Brain volume
Nuclear Magnetic Resonance (NMR) Total brain volume, hippocampal volume, and volume of white matter hyperintense lesions will be evaluated in a subsample of participants. NMR have allowed important advances in the understanding of age-related brain changes. NMR is a non-invasive instrument that allows the study of the normal aging of individuals at different times of their lives (Barnes et al. 2023).
Time frame: Visit 1 (week 0), visit 10 (week 36)
Cognitive ability assessment
BDNF Brain-derived Neutrophic Factor (pg/ml) will be analyzed by Enzyme-linked immunosorbent assay ELISA kit in blood samples
Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)
Skeletal muscle strength
Isokinetic. Isokinetic test: the evaluation was conducted with an isokinetic dynamometer using a gold standard method (Biodex System 4; Biodex Medical Systems, NewYork, USA) by five repetitions sat two angular velocities (180°s-1, and240°s-1) (Solà et al., 2015). This allows a quantitative evaluation of muscle function through variables such as torque, work and power.
Time frame: Visit 1 (week 0), visit 10 (week 36)
Muscle mass, wasting and turnover
Muscle mass (skeletal muscle mass (kg)) assessed by Bioimpedance TANITA (MC-780MA; Tanita Corp., Tokyo, Japan).
Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)
Muscle mass, wasting and turnover
Muscle mass (appendicular skeletal muscle mass (kg)) assessed by Bioimpedance TANITA (MC-780MA; Tanita Corp., Tokyo, Japan).
Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)
Muscle mass, wasting and turnover
Muscle mass (skeletal muscle mass index (kg/m2)) assessed by Bioimpedance TANITA (MC-780MA; Tanita Corp., Tokyo, Japan).
Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)
Muscle mass, wasting and turnover
Muscle mass (appedicular skeletal muscle mass index (kg/m2)) assessed by Bioimpedance TANITA (MC-780MA; Tanita Corp., Tokyo, Japan).
Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)
Muscle mass, wasting and turnover
Muscle mass assessed by ultrasound (VINNO 5 (Vinno (Suzhou) Co., Ltd., China)
Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)
Muscle mass, wasting and turnover
Creatine kinase (U/L) assessed by enzymatic assays in a Cobas Mira Plus autoanalyzer (Roche Diagnostics Systems, Madrid, Spain).
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Muscle mass, wasting and turnover
Cystatin-C (mg/L) assessed by enzymatic assays in a Cobas Mira Plus autoanalyzer (Roche Diagnostics Systems, Madrid, Spain).
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Muscle mass, wasting and turnover
Serum Myostatin (ng/ml) assessed by commercial ELISA kits (Muscari et al., 2023)
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Muscle mass, wasting and turnover
Serum Follistatin (ng/ml) assessed by commercial ELISA kits (Muscari et al., 2023)
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Physical performance
Gait speed (m/s) assessed by the length of the walking course divided by the time (Ladang et al., 2023).
Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)
Signalling pathways in skeletal muscle
Muscle gene expression. A muscle biopsy (200-225 mg) will be obtained from a subgroup of volunteers (n=15/group) by trained physicians (Harper et al., 2021). After collection, these samples will be immediately snap frozen in liquid nitrogen and stored at -80°C prior to analysis. To confirm RNA sequencing results obtained in the animal model of age-associated sarcopenia (transcriptomic approach that will be carried out in gastrocnemius skeletal muscle as described in task 5.2), real-time gene expression analysis (qPCR) will be performed, as previously described (Pérez-Matute et al., 2016).
Time frame: Visit 1 (week 0), visit 10 (week 36)
Biological age marker (Aging biomarker)
Serum N-terminal pro-brain natriuretic peptide (NT-proBNP) (pg/ml) in blood samples (Muscari et al., 2023) is used to diagnose and establish prognosis for heart failure and is a promising biomarker of biological age as it correlates with chronological age and predict life span better than chronological age.
Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)
Glucose homeostasis
FBG (mmol/L) assessed by standardized methods in an automated analyzer (Beckman Coulter-Synchron, Galway, Ireland) in blood samples
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Glucose homeostasis
Insulin (IU/mL) assessed by standardized methods in an automated analyzer (Beckman Coulter-Synchron, Galway, Ireland) in blood samples
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Glucose homeostasis
HGBA1c (%) assessed by standardized methods in an automated analyzer (Beckman Coulter-Synchron, Galway, Ireland) in blood samples
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Glucose homeostasis
HOMA index calculated (Winell et al., 2010) in blood samples
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Glucose homeostasis
IGF-1 (ng/ml) levels were measured using Human IGF-1 Quantikine ELISA Kit (Pérez-Matute et al., 2022) in blood samples
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Lipid profile
Total cholesterol (mmol/L) in blood samples assessed by standardized enzymatic automated methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland)
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Lipid profile
HDLc (mmol/L) in blood samples assessed by standardized enzymatic automated methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland)
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Lipid profile
LDLc (mmol/L) in blood samples assessed by standardized enzymatic automated methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland)
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Lipid profile
VLDLc (mmol/L) in blood samples assessed by standardized enzymatic automated methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland)
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Lipid profile
Total TG (mmol/L) in blood samples assessed by standardized enzymatic automated methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland)
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Lipid profile
NEFA (mmol/L) in blood samples assessed by standardized enzymatic automated methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland)
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Lipid profile
ApoA1 (mg/dL) in blood samples assessed by standardized enzymatic automated methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland)
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Lipid profile
ApoB100 (mg/dL) in blood samples assessed by standardized enzymatic automated methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland)
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Lipid profile
Apo B100/Apo A1 ratio in blood samples assessed by standardized enzymatic automated methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland)
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Lipid profile
Lp (a) (mg/dL) in blood samples assessed by standardized enzymatic automated methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland)
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Stress Response and Mitochondria
GDF15 (pg/mL) Growth differentiating factor 15 is recgonized in mitochondria dysfunction, and as biomarker of aging (Justice et al., 2018) in blood samples
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Oxidative markers
OxLDL (ug/mL) assessed by commercial ELISA in blood samples
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Oxidative markers
MetSO/Met (ng/mL) assessed by commercial ELISA in blood samples
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Oxidative markers
SOD (U/g Hb) 20uL (abcam) in plasma EDTA blood samples assessed by enzymatic assays (Hissin et al., 1976)
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Oxidative markers
GSHPx (nmol/mL) 50uL (abcam) plasma EDTA blood samples enzymatic assays (Hissin et al., 1976)
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Oxidative markers
CoQ10 (ug/mL) in blood samples assessed by HPLC
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Inflammation markers
IL-6 (pg/mL) assessed by immunoturbidimetry on an autoanalyzer (Roche Diagnostics Systems, Madrid, Spain) in blood samples
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Inflammation markers
hsCRP (mg/L) assessed by immunoturbidimetry on an autoanalyzer (Roche Diagnostics Systems, Madrid, Spain) in blood samples
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Inflammation markers
TNFRII (pg/mL) assessed by commercial ELISA in blood samples
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Inflammation markers
Adiponectin (ug/mL) assessed by standardized enzymatic automated methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland) in blood samples
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Inflammation markers
Uric acid (mg/dL) assessed by standardized enzymatic automated methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland) in blood samples
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Vascular parameters
Systolic and diastolic blood pressure (SBP and DBP) (mm Hg) and pulse pressure (PP) (mm Hg) assessed by automatic sphygmomanometer (OMRON HEM-907; Peroxfarma, Barcelona, Spain).
Time frame: Visit 0, visit 1Visit 0 (week -1), visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36), visit 4, visit 7, visit 10
Biomarkers of endothelial dysfunction
E-selectin (CD62E) (ng/mL) assessed by Commercial ELISA and multi-analyte ELISArray kits as described in our previous work (Catalán et al., 2015) in blood samples
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Biomarkers of endothelial dysfunction
P-selectin (CD62P) (ng/mL) assessed by Commercial ELISA and multi-analyte ELISArray kits as described in our previous work (Catalán et al., 2015) in blood samples
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Biomarkers of endothelial dysfunction
ICAM-1 (CD54) (ng/mL) assessed by Commercial ELISA and multi-analyte ELISArray kits as described in our previous work (Catalán et al., 2015) in blood samples
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Biomarkers of endothelial dysfunction
VCAM-1 (CD106) (ng/mL) assessed by Commercial ELISA and multi-analyte ELISArray kits as described in our previous work (Catalán et al., 2015) in blood samples
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Faecal microbial composition
Metataxonomic profile.
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Faecal microbial function
Microbial functional profile
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Faecal metabolome
SCFA acetic, butyric, propionic, isobutyric, valeric, isovaleric and caproic acid and phenol colonic metabolites
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
DNA methylation
Epigeneitc age. Total genomic DNA will be extracted from saliva samples using the Norgen Saliva DNA Isolation Kit.
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Gut permeability determined on plasma
Zonulin (ng/mL). Human zonulin levels will be quantified using an ELISA kit (Cusabio® Technology Llc, Houston, TX, USA)
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Biomarkers of wine intake compliance
Quantification of urine phenol metabolites in human elderly
Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)
Not enrolling at this site.
Not enrolling at this site.
Plan to share: No
Started Mar 2025 (actual). Primary completion is estimated for Sep 2026, 18 months after the start.
Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 18 months is below that.
Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Rovira i Virgili